Select publications

Coiffier B et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235-42. Abstract

Habermann TM et al. Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years of age or older with diffuse large B-cell lymphoma (DLBCL): An update. Proc ASH 2004;Abstract 127.

Kaminski MS et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352(5):441-9. Abstract

Pfreundschuh MG et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study. Proc ASCO 2005;Abstract 6529.

Press OW et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911. Blood 2003;102(5):1606-12. Abstract

Sehn LH et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23(22):5027- 33. Abstract

Van Oers MHJ et al. Chimeric anti-CD20 monoclonal antibody (rituximab; Mabtheraâ) in remission induction and maintenance treatment of relapsed /resistant follicular non-Hodgkin’s lymphoma: A Phase III randomized Intergroup clinical trial. Proc ASH 2004;Abstract 586.

Zelenetz AD et al. Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab/iodine I131 I-tositumomab followed by CHOP chemotherapy results in a high complete remission rate. Proc ASH 2003;Abstract 1477.